AI in Pathology Market Set for Strong Growth Through 2034 as Digital Diagnostics, Automation and Precision Medicine Unlock New Opportunities

Cancer caseloads, pathologist shortages, digital adoption and regulatory clearances are driving AI diagnostics, biomarker tools and workflow Software AG , with Asia-Pacific a key opportunity.

Dublin, Sept. 18, 2026 (GLOBE NEWSWIRE) -- "Artificial Intelligence (AI) in Pathology - Market Insights, Competitive Landscape, and Market Forecast - 2034" has been added to ResearchAndMarkets.com's offering.

AI in Pathology Market Size, Share, Growth and Forecast, 2026-2034

The global AI in pathology market was valued at approximately USD 0.13 billion in 2025 and is projected to reach USD 0.95 billion by 2034, expanding at a compound annual growth rate (CAGR) of 24.7% from 2026 to 2034. Market growth is supported by increasing cancer incidence, rising pathology workloads, shortages of qualified pathologists, broader adoption of digital pathology and continued regulatory progress for AI-enabled diagnostic Software AG .

Software AG led the AI in pathology market with a 51% revenue share in 2025. Machine learning accounted for 45% of the market by technology, while disease diagnosis and prognosis represented the leading application with a 58% share. Hospitals and reference laboratories were the largest end-user category, accounting for 47% of revenue. North America held the highest regional share at 41%, while Asia-Pacific is expected to record the fastest growth through 2034.

AI in Pathology Market Growth Drivers

The rising global cancer burden remains a major market driver. The International Agency for Research on Cancer recorded approximately 20 million new cancer cases in 2022 and projects that annual cases could reach 35 million by 2050. Higher incidence is increasing biopsy volumes and demand for tissue analysis, tumor grading, immunohistochemistry scoring and biomarker assessment.

Workforce constraints are also accelerating AI adoption. Hospitals, diagnostic laboratories and pathology networks face growing caseloads, delayed turnaround times and uneven access to specialists. AI-enabled platforms can support case prioritization, cancer detection, tumor grading, biomarker quantification, quality control and digital reporting. These capabilities help laboratories improve productivity and diagnostic consistency without requiring proportional increases in staffing.

Digital pathology adoption provides the infrastructure required for scalable AI deployment. Investment in whole-slide imaging, image-management platforms, cloud computing and laboratory-system integration is enabling healthcare organizations to implement AI across multi-site networks. Regulatory authorizations and EU IVDR certifications are also strengthening clinical confidence and expanding commercial access for validated pathology applications.

Precision oncology and companion diagnostics represent additional growth opportunities. Pharmaceutical and biotechnology companies increasingly use computational pathology in biomarker discovery, clinical trials and therapeutic development. Foundation models and generative AI systems trained on large slide datasets could further expand applications in cancer detection, outcome prediction, treatment selection and pathology reporting.

Market Restraints and Adoption Challenges

Despite strong growth prospects, the AI in pathology market faces capital, regulatory and operational barriers. Digital conversion requires slide scanners, data storage, computing capacity, cybersecurity safeguards and integration with laboratory information systems. These costs can limit adoption among smaller laboratories and healthcare providers in lower-resource markets.

AI diagnostic products must also satisfy demanding clinical-validation and regulatory requirements. Developers must demonstrate accuracy, reproducibility and generalizability across scanners, institutions and patient populations. Interoperability gaps, proprietary image formats and inconsistent technical standards can complicate deployment. Additional challenges include algorithmic bias, data-governance obligations, limited specialist talent, clinician trust and uneven reimbursement for AI-supported pathology services.

AI in Pathology Market Segment Analysis

By offering: Software AG generated 51% of market revenue in 2025, supported by demand for diagnostic algorithms, image-management platforms, cloud-based collaboration and recurring subscription services. Software AG is expected to retain its leadership as laboratories add cancer-detection, grading and biomarker-analysis modules to existing digital pathology systems. Hardware includes slide scanners, servers and computing infrastructure, while services cover implementation, integration, validation and managed analytics.

By technology: Machine learning held a 45% share in 2025 and remained the leading technology category. Its position reflects broad use in clinically validated applications for image classification, cancer detection, grading and quantitative analysis. Deep learning and computer vision continue to advance, while generative AI and foundation models are gaining attention for biomarker discovery, multi-tissue analysis and diagnostic support.

By application: Disease diagnosis and prognosis led the market with a 58% share in 2025. Oncology pathology represents a central source of demand due to increasing cancer incidence and the expanding role of biomarker-guided treatment. Other important applications include drug discovery and development, companion diagnostics, workflow optimization and quality control.

By end user: Hospitals and reference laboratories accounted for 47% of the market in 2025. Their leadership is supported by high testing volumes, established digital infrastructure and the need to coordinate pathology services across multiple sites. Diagnostic laboratories, pharmaceutical and biotechnology companies, and academic research institutes are also increasing investment in AI-enabled pathology.

Regional AI in Pathology Market Outlook

North America dominated the global AI in pathology market with a 41% revenue share in 2025. The region benefits from advanced healthcare infrastructure, substantial investment in precision oncology, widespread digital pathology adoption and a large concentration of technology developers. FDA authorizations, strategic collaborations and enterprise deployments across hospitals and laboratory networks reinforce regional leadership.

Europe is an established market led by Germany, the United Kingdom, France, Italy and Spain. Growth is supported by public healthcare digitization, clinical research networks and EU IVDR certification of pathology technologies. The region also has a strong base of AI and image-analysis developers.

Asia-Pacific is forecast to be the fastest-growing regional market through 2034. Expansion is being driven by rising cancer incidence, shortages of pathologists, government digital-health programs and increasing healthcare investment across China, Japan, India, South Korea and Australia. Telepathology and locally developed platforms may improve diagnostic access across underserved and geographically dispersed populations.

Latin America, the Middle East and Africa represent emerging opportunities. Growing cancer workloads, constrained laboratory capacity and specialist shortages are increasing interest in digital pathology, remote collaboration and AI-assisted analysis. Adoption will depend on infrastructure investment, regulatory development and access to cost-effective technologies.

Competitive Landscape

The AI in pathology market is moderately concentrated, combining major diagnostics companies with specialized Software AG developers. Competition centers on regulatory approvals, clinical evidence, image-management capabilities, algorithm performance, interoperability, cloud deployment and access to high-quality pathology datasets.

• Tempus AI, Inc. and Paige
• F. Hoffmann-La Roche Ltd
• Philips N.V.
• PathAI, Inc.
• Ibex Medical Analytics Ltd.
• Proscia Inc.
• Indica Labs, Inc.
• Aiforia Technologies Plc
• Hologic , Inc.
• Visiopharm A/S

Strategic partnerships and acquisitions are shaping competition. In August 2025, Tempus AI completed its acquisition of Paige, combining Paige's digitized pathology-slide resources with Tempus' multiomic data to support oncology foundation-model development. During the same month, PathAI and Moffitt Cancer Center announced a multi-year partnership to deploy the AISight Dx digital pathology platform across Moffitt's pathology operations.

AI in Pathology Market Segmentation

• Offering: Software AG , hardware and services
• Technology: Machine learning, deep learning, computer vision, generative and foundation models, and other technologies
• Application: Disease diagnosis and prognosis, oncology pathology, non-oncologic pathology, drug discovery and development, companion diagnostics, workflow management and quality control
• End user: Hospitals and reference laboratories, diagnostic laboratories, pharmaceutical and biotechnology companies, research institutes and academic organizations
• Geography: North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa

Key AI in Pathology Market Takeaways

• The market is projected to grow from USD 0.13 billion in 2025 to USD 0.95 billion by 2034.
• The forecast CAGR is 24.7% from 2026 to 2034.
• Software AG led the offering segment with a 51% share in 2025.
• Machine learning held a 45% technology share in 2025.
• Disease diagnosis and prognosis led applications with a 58% share.
• Hospitals and reference laboratories accounted for 47% of end-user revenue.
• North America led with a 41% regional share, while Asia-Pacific is forecast to grow fastest.

The long-term outlook for the AI in pathology market remains strong as cancer incidence, diagnostic complexity and laboratory workloads continue to increase. Successful market participants will be positioned to deliver clinically validated, interoperable and secure platforms that integrate with existing pathology workflows while demonstrating measurable improvements in quality, efficiency and patient care.

Key Topics Covered:

1. AI in Pathology Market Report Introduction
1.1 Scope of the Study
1.2 Market Segmentation
1.3 Market Assumptions

2. AI in Pathology Market Executive Summary
2.1 Market at a Glance

3. AI in Pathology Market Key Factors Analysis
3.1 AI in Pathology Market Drivers
3.1.1 Rising Global Cancer Burden and Slide Volumes
3.1.2 Worsening Shortage of Pathologists
3.1.3 Accelerating Regulatory Clearances
3.1.4 Transition to Digital Pathology and Foundation Models
3.2 AI in Pathology Market Restraints and Challenges
3.2.1 High Capital and Infrastructure Requirements
3.2.2 Regulatory, Validation, and Trust Barriers
3.2.3 Interoperability, Workforce, and Reimbursement Gaps
3.3 AI in Pathology Market Opportunities
3.3.1 Foundation Models and Generative AI Co-Pilots
3.3.2 Emerging-Market and Telepathology Expansion

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis
5.1 United States
5.2 Europe
5.3 Japan
5.4 China

6. AI in Pathology Market Porter's Five Forces Analysis
6.1 Bargaining Power of Suppliers
6.2 Bargaining Power of Buyers
6.3 Threat of New Entrants
6.4 Threat of Substitutes
6.5 Competitive Rivalry

7. AI in Pathology Market Assessment
7.1 By Offering
7.1.1 Software AG
7.1.2 Hardware
7.1.3 Services
7.2 By Technology
7.2.1 Machine Learning
7.2.2 Deep Learning
7.2.3 Computer Vision
7.2.4 Generative and Foundation Models
7.2.5 Others
7.3 By Application
7.3.1 Disease Diagnosis and Prognosis
7.3.1.1 Oncology Pathology
7.3.1.2 Non-Oncologic Pathology
7.3.2 Drug Discovery and Development
7.3.3 Companion Diagnostics
7.3.4 Workflow and Quality Control
7.3.5 Others
7.4 By End User
7.4.1 Hospitals and Reference Laboratories
7.4.2 Diagnostic Laboratories
7.4.3 Pharmaceutical and Biotechnology Companies
7.4.4 Research and Academic Institutes
7.4.5 Others
7.5 By Geography
7.5.1 North America
7.5.1.1 United States AI in Pathology Market Size in USD million (2023-2034)
7.5.1.2 Canada AI in Pathology Market Size in USD million (2023-2034)
7.5.1.3 Mexico AI in Pathology Market Size in USD million (2023-2034)
7.5.2 Europe
7.5.2.1 Germany AI in Pathology Market Size in USD million (2023-2034)
7.5.2.2 United Kingdom AI in Pathology Market Size in USD million (2023-2034)
7.5.2.3 France AI in Pathology Market Size in USD million (2023-2034)
7.5.2.4 Italy AI in Pathology Market Size in USD million (2023-2034)
7.5.2.5 Spain AI in Pathology Market Size in USD million (2023-2034)
7.5.2.6 Rest of Europe AI in Pathology Market Size in USD million (2023-2034)
7.5.3 Asia-Pacific
7.5.3.1 China AI in Pathology Market Size in USD million (2023-2034)
7.5.3.2 Japan AI in Pathology Market Size in USD million (2023-2034)
7.5.3.3 India AI in Pathology Market Size in USD million (2023-2034)
7.5.3.4 Australia AI in Pathology Market Size in USD million (2023-2034)
7.5.3.5 South Korea AI in Pathology Market Size in USD million (2023-2034)
7.5.3.6 Rest of Asia-Pacific AI in Pathology Market Size in USD million (2023-2034)
7.5.4 Rest of World
7.5.4.1 Middle East AI in Pathology Market Size in USD million (2023-2034)
7.5.4.2 Africa AI in Pathology Market Size in USD million (2023-2034)
7.5.4.3 South America AI in Pathology Market Size in USD million (2023-2034)

8. AI in Pathology Market Competitive Landscape
8.1 Market Concentration and Structure
8.2 Competitive Positioning and Market Share Analysis ( PREMIUM Offering)

9. AI in Pathology Market Startup Funding and Investment Trends

10. AI in Pathology Market Company and Product Profiles
10.1 Tempus AI, Inc. (Paige)
10.1.1 Company Overview
10.1.2 Company Snapshot
10.1.3 Financial Overview
10.1.4 Product Portfolio
10.1.5 Strategic Initiatives / Entropy
10.2 F. Hoffmann-La Roche Ltd
10.2.1 Company Overview
10.2.2 Company Snapshot
10.2.3 Financial Overview
10.2.4 Product Portfolio
10.2.5 Strategic Initiatives / Entropy
10.3 Philips N.V.
10.3.1 Company Overview
10.3.2 Company Snapshot
10.3.3 Financial Overview
10.3.4 Product Portfolio
10.3.5 Strategic Initiatives / Entropy
10.4 PathAI, Inc.
10.4.1 Company Overview
10.4.2 Company Snapshot
10.4.3 Financial Overview
10.4.4 Product Portfolio
10.4.5 Strategic Initiatives / Entropy
10.5 Ibex Medical Analytics Ltd.
10.5.1 Company Overview
10.5.2 Company Snapshot
10.5.3 Financial Overview
10.5.4 Product Portfolio
10.5.5 Strategic Initiatives / Entropy
10.6 Proscia Inc.
10.6.1 Company Overview
10.6.2 Company Snapshot
10.6.3 Financial Overview
10.6.4 Product Portfolio
10.6.5 Strategic Initiatives / Entropy
10.7 Indica Labs, Inc.
10.7.1 Company Overview
10.7.2 Company Snapshot
10.7.3 Financial Overview
10.7.4 Product Portfolio
10.7.5 Strategic Initiatives / Entropy
10.8 Aiforia Technologies Plc
10.8.1 Company Overview
10.8.2 Company Snapshot
10.8.3 Financial Overview
10.8.4 Product Portfolio
10.8.5 Strategic Initiatives / Entropy
10.9 Hologic , Inc.
10.9.1 Company Overview
10.9.2 Company Snapshot
10.9.3 Financial Overview
10.9.4 Product Portfolio
10.9.5 Strategic Initiatives / Entropy
10.10 Visiopharm A/S
10.10.1 Company Overview
10.10.2 Company Snapshot
10.10.3 Financial Overview
10.10.4 Product Portfolio
10.10.5 Strategic Initiatives / Entropy

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.

11. KOL Views

12. Project Approach

13. About the Publisher

14. Disclaimer and Contact Us

List of Tables
Table 1: AI in Pathology Market in Global (2023-2034)
Table 2: AI in Pathology Market in Global by Offering (2023-2034)
Table 3: AI in Pathology Market in Global by Technology (2023-2034)
Table 4: AI in Pathology Market in Global by Application (2023-2034)
Table 5: AI in Pathology Market in Global by End User (2023-2034)
Table 6: AI in Pathology Market in Global by Geography (2023-2034)
Table 7: AI in Pathology Market in North America (2023-2034)
Table 8: AI in Pathology Market in the United States (2023-2034)
Table 9: AI in Pathology Market in Canada (2023-2034)
Table 10: AI in Pathology Market in Mexico (2023-2034)
Table 11: AI in Pathology Market in Europe (2023-2034)
Table 12: AI in Pathology Market in Germany (2023-2034)
Table 13: AI in Pathology Market in United Kingdom (2023-2034)
Table 14: AI in Pathology Market in France (2023-2034)
Table 15: AI in Pathology Market in Italy (2023-2034)
Table 16: AI in Pathology Market in Spain (2023-2034)
Table 17: AI in Pathology Market in the Rest of Europe (2023-2034)
Table 18: AI in Pathology Market in Asia-Pacific (2023-2034)
Table 19: AI in Pathology Market in China (2023-2034)
Table 20: AI in Pathology Market in Japan (2023-2034)
Table 21: AI in Pathology Market in India (2023-2034)
Table 22: AI in Pathology Market in Australia (2023-2034)
Table 23: AI in Pathology Market in South Korea (2023-2034)
Table 24: AI in Pathology Market in Rest of Asia-Pacific (2023-2034)
Table 25: AI in Pathology Market in the Rest of the World (2023-2034)
Table 26: AI in Pathology Market in the Middle East (2023-2034)
Table 27: AI in Pathology Market in Africa (2023-2034)
Table 28: AI in Pathology Market in South America (2023-2034)
Table 29: Competitive Landscape
Table 30: Startup Funding and Investment Trends

List of Figures
Figure 1: AI in Pathology Market Drivers
Figure 2: AI in Pathology Market Restraints
Figure 3: AI in Pathology Market Opportunities
Figure 4: Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
Figure 5: Regulatory Analysis (US, EU, Japan, China)
Figure 6: Porter's Five Forces Analysis
Figure 7: Competitive Analysis
Figure 8: AI in Pathology Market in Global (2023-2034)
Figure 9: AI in Pathology Market in Global by Offering (2023-2034)
Figure 10: AI in Pathology Market in Global by Technology (2023-2034)
Figure 11: AI in Pathology Market in Global by Application (2023-2034)
Figure 12: AI in Pathology Market in Global by End User (2023-2034)
Figure 13: AI in Pathology Market in Global by Geography (2023-2034)
Figure 14: AI in Pathology Market in North America (2023-2034)
Figure 15: AI in Pathology Market in the United States (2023-2034)
Figure 16: AI in Pathology Market in Canada (2023-2034)
Figure 17: AI in Pathology Market in Mexico (2023-2034)
Figure 18: AI in Pathology Market in Europe (2023-2034)
Figure 19: AI in Pathology Market in Germany (2023-2034)
Figure 20: AI in Pathology Market in United Kingdom (2023-2034)
Figure 21: AI in Pathology Market in France (2023-2034)
Figure 22: AI in Pathology Market in Italy (2023-2034)
Figure 23: AI in Pathology Market in Spain (2023-2034)
Figure 24: AI in Pathology Market in the Rest of Europe (2023-2034)
Figure 25: AI in Pathology Market in Asia-Pacific (2023-2034)
Figure 26: AI in Pathology Market in China (2023-2034)
Figure 27: AI in Pathology Market in Japan (2023-2034)
Figure 28: AI in Pathology Market in India (2023-2034)
Figure 29: AI in Pathology Market in Australia (2023-2034)
Figure 30: AI in Pathology Market in South Korea (2023-2034)
Figure 31: AI in Pathology Market in Rest of Asia-Pacific (2023-2034)
Figure 32: AI in Pathology Market in the Rest of the World (2023-2034)
Figure 33: AI in Pathology Market in the Middle East (2023-2034)
Figure 34: AI in Pathology Market in Africa (2023-2034)
Figure 35: AI in Pathology Market in South America (2023-2034)
Figure 36: Competitive Landscape
Figure 37: Startup Funding and Investment Trends

A selection of companies mentioned in this report includes, but is not limited to:

• Tempus AI, Inc. (Paige)
• F. Hoffmann-La Roche Ltd
• Philips N.V.
• PathAI, Inc.
• Ibex Medical Analytics Ltd.
• Proscia Inc.
• Indica Labs, Inc.
• Aiforia Technologies Plc
• Hologic , Inc.
• Visiopharm A/S

For more information about this report visit https://www.researchandmarkets.com/r/hi3w64

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood, Senior  Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900